Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 9, 2015, Pages 5681-5696

  Abuhelwa, Ahmad Y ^a   Foster, David J R ^a   Mudge, Stuart ^b   Hayes, David ^b   Upton, Richard N ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b Mayne Pharma International   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYITRACONAZOLE; ITRACONAZOLE; MICROCAPSULE;

ABSORPTION RATE CONSTANT; ADULT; ARTICLE; BIOEQUIVALENCE; COMPARTMENT MODEL; COMPETITIVE INHIBITION; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG CLEARANCE; DRUG ELIMINATION; DRUG FORMULATION; DRUG MEGADOSE; FEMALE; FOOD; HUMAN; MALE; MICHAELIS MENTEN KINETICS; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; POWER ANALYSIS; PRIORITY JOURNAL; SINGLE DRUG DOSE; ADOLESCENT; ANALOGS AND DERIVATIVES; CHEMISTRY; CONTROLLED STUDY; MICROCAPSULE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; THEORETICAL MODEL; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CAPSULES; CROSS-OVER STUDIES; FEMALE; HEALTHY VOLUNTEERS; HUMANS; ITRACONAZOLE; MALE; MIDDLE AGED; MODELS, THEORETICAL; YOUNG ADULT;

EID: 84940908946     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00973-15     Document Type: Article

References (56)

1. Potter M, Donnelly J. 2003. The role of itraconazole in preventing and treating systemic fungal infections in immunocompromised patients. Acta Haematol 111:175-180.
2. Glasmacher A, Prentice A, Gorschlüter M, Engelhart S, Hahn C, Djulbegovic B, Schmidt-Wolf IG. 2003. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol 21:4615-4626. http://dx.doi.org/10.1200/JCO.2003.04.052.
3. Grant SM, Clissold SP. 1989. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in superficial and systemic mycoses. Drugs 37:310-344.
4. Isoherranen N, Kunze KL, Allen KE, Nelson WL, Thummel KE. 2004. Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos 32:1121-1131. http://dx.doi.org/10.1124/dmd.104.000315.
5. Janssen Pharmaceuticals, Inc. Sporanox (itraconazole) capsules. Janssen Pharmaceuticals, Inc., Beerse, Belgium.
6. Mayne Pharma International Pty Ltd. Lozanoc 50mg capsules: consumer medicine information. Mayne Pharma International Pty Ltd., South Australia, Australia. http://www.betterhealth.vic.gov.au/bhcv2/bhc med.nsf/ead67cc7ba5c3879ca257e4200114a2d/61a46805f1332ea9ca257e 4200118bc2?OpenDocument.
7. Jaruratanasirikul S, Sriwiriyajan S. 1998. Effect of omeprazole on the pharmacokinetics of itraconazole. Eur J Clin Pharmacol 54:159-161. http: //dx.doi.org/10.1007/s002280050438.
8. Lohitnavy M, Lohitnavy O, Thangkeattiyanon O, Srichai W. 2005. Reduced oral itraconazole bioavailability by antacid suspension. J Clin Pharm Ther 30:201-206. http://dx.doi.org/10.1111/j.1365-2710.2005.00632.x.
9. Hardin TC, Graybill JR, Fetchick R, Woestenborghs R, Rinaldi MG, Kuhn JG. 1988. Pharmacokinetics of itraconazole following oral admin istration to normal volunteers. Antimicrob Agents Chemother 32:1310-1313. http://dx.doi.org/10.1128/AAC.32.9.1310.
10. Mouton J, van Peer A, de Beule K, Van Vliet A, Donnelly JP, Soons PA. 2006. Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation. Antimicrob Agents Chemother 50:4096-4102. http://dx.doi.org/10.1128 /AAC.00630-06.
11. Yun H-Y, Baek MS, Park IS, Choi BK, Kwon K-I. 2006. Comparative analysis of the effects of rice and bread meals on bioavailability of itraconazole using NONMEM in healthy volunteers. Eur J Clin Pharmacol 62: 1033-1039. http://dx.doi.org/10.1007/s00228-006-0200-5.
12. Zimmermann T, Yeates R, Laufen H, Pfaff G, Wildfeuer A. 1994. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol 46:147-150.
13. Zimmermann T, Yeates R, Albrecht M, Laufen H, Wildfeuer A. 1993. Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in Japanese subjects. Int J Clin Pharmacol Res 14:87-93.
14. Bae SK, Park SJ, Shim EJ, Mun JH, Kim EY, Shin JG, Shon JH. 2011. Increased oral bioavailability of itraconazole and its active metabolite, 7-hydroxyitraconazole, when coadministered with a vitamin C beverage in healthy participants. J Clin Pharmacol 51:444-451. http://dx.doi.org /10.1177/0091270010365557.
15. European Medicines Agency (EMEA). 1996. Note for guidance on good clinical practice (CPMP/ICH/135/95). European Medicines Agency, London, United Kingdom.
16. World Medical Association Declaration of Helsinki. 1997. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 277:925-926. http://dx.doi.org/10.1001/jama .1997.03540350075038.
17. Beal S, Sheiner LB, Boeckmann A, Bauer RJ. 2009.NONMEMuser's guides, part V. (1989-2009), Icon Development Solutions, Ellicott City, MD.
18. R Core Team. 2014. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
19. Wickham H. 2007. Reshaping data with the {reshape} package. J Stat Softw 21:1-20.
20. Wickham H. 2009. ggplot2: elegant graphics for data analysis. Springer- Verlag, New York, NY.
21. Wickham H. 2011. The split-apply-combine strategy for data analysis. J Stat Softw 40:1-29.
22. H?jsgaard S, Halekoh U, Robison-Cox J, Wright K, Leidi AA. 2014. doBy: groupwise summary statistics, LSmeans, linear contrasts, utilities. http://cran.r-project.org/web/packages/doBy/index.html.
23. Wickham H. 2014. Package 'scales. Scale functions for graphics. http: //cran.r-project.org/web/packages/scales/scales.pdf.
24. Mould DR, Upton RN. 2013. Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol 2:e38. http://dx.doi.org/10.1038/psp.2013.14.
25. Savic RM, Jonker DM, Kerbusch T, Karlsson MO. 2007. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn 34:711-726. http://dx.doi.org/10.1007/s10928-007-9066-0.
26. Gabrielsson J, Weiner D. 2001. Pharmacokinetic and pharmacodynamic data analysis: concepts and applications, vol 2. CRC Press, Boca Raton, FL.
27. Mandema JW, Verotta D, Sheiner LB. 1992. Building population pharmacokinetic- pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm 20:511-528.
28. Zhang L, Beal SL, Sheiner LB. 2003. Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance. J Pharmacokinet Pharmacodyn 30:387-404. http://dx.doi.org/10.1023/B:JOPA.000001299 8.04442.1f.
29. Ette EI. 1997. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 37:486-495. http://dx.doi.org/10.1002/j.1552 -4604.1997.tb04326.x.
30. Wojciechowski J, Hopkins A, Upton R. 2015. Interactive pharmacometric applications using R and the shiny package. CPT Pharmacometrics Syst Pharmacol 4:e00021.
31. Chang W, Cheng J, Allaire JJ, Xie Y, McPherson J, RStudio, jQuery Foundation, jQuery contributors, jQuery UI contributors, Otto M, Thornton J, Bootstrap contributors, Twitter, Inc. Farkas A, Jehl S, Petre S, Rowls A, Gandy D, Reavis B, Kowal KM, es5-shim contributors, Ineshin D, SpryMedia Ltd., Fraser J, Gruber J, Sagalaev I, R Core Team. 2015. shiny:Webapplication framework for R.Rpackage version 0.10.1.R Core Team, Vienna, Austria. http://CRAN.R-project.org/package-shiny.
32. Abuhelwa AY, Foster DJ, Upton RN. 2015. ADVAN-style analytical solutions for common pharmacokinetic models. J Pharmacol Toxicol Methods 73:42-48. http://dx.doi.org/10.1016/j.vascn.2015.03.004.
33. Beal SL. 2001. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 28:481-504. http://dx.doi .org/10.1023/A:1012299115260.
34. Lehr T, Staab A, Trommeshauser D, Schaefer HG, Kloft C. 2010. Semi-mechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazole. Clin Pharmacokinet 49:53-66. http://dx.doi.org/10.2165/11317210-000000000-00000.
35. Hennig S, Waterhouse TH, Bell SC, France M, Wainwright CE, Miller H, Charles BG, Duffull SB. 2007. A D-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. Br J Clin Pharmacol 63:438-450. http://dx.doi.org/10.1111/j.1365-2125 .2006.02778.x.
36. Koks CH, Huitema AD, Kroon ED, Chuenyam T, Sparidans RW, Lange JM, Beijnen JH. 2003. Population pharmacokinetics of itraconazole in Thai HIV-1-infected persons. Ther Drug Monit 25:229-233. http://dx.doi .org/10.1097/00007691-200304000-00014.
37. Kanbayashi Y, Nomura K, Fujimoto Y, Shimura K, Shimizu D, Okamoto K, Matsumoto Y, Horiike S, Shimazaki C, Takagi T. 2008. Population pharmacokinetics of itraconazole solution used as prophylaxis for febrile neutropenia. Int J Antimicrob Agents 31:452-457. http://dx.doi .org/10.1016/j.ijantimicag.2007.12.017.
38. Hennig S, Wainwright CE, Bell SC, Miller H, Friberg LE, Charles BG. 2006. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. Clin Pharmacokinet 45:1099-1114. http://dx.doi.org /10.2165/00003088-200645110-00004.
39. Lee DG, Chae H, Yim DS, Park S, Choi SM, Kim S, Choi JH, Yoo JH, Shin WS. 2009. Population pharmacokinetics of intravenous itraconazole in patients with persistent neutropenic fever. J Clin Pharm Ther 34:337-344. http://dx.doi.org/10.1111/j.1365-2710.2008.00999.x.
40. Yamagishi Y, Hamada Y, Hagihara M, Mikamo H. 2013. Population pharmacokinetics of itraconazole in Japanese patients with invasive fungal peritonitis. Jpn J Antibiot 66:159-168.
41. Zanger UM, Schwab M. 2013. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103-141. http://dx.doi.org/10 .1016/j.pharmthera.2012.12.007.
42. Kohri N, Yamayoshi Y, Xin H, Iseki K, Sato N, Todo S, Miyazaki K. 1999. Improving the oral bioavailability of albendazole in rabbits by the solid dispersion technique. J Pharm Pharmacol 51:159-164. http://dx.doi .org/10.1211/0022357991772277.
43. Kondo N, Iwao T, Hirai KI, Fukuda M, Yamanouchi K, Yokoyama K, Miyaji M, Ishihara Y, Kon K, Ogawa Y. 1994. Improved oral absorption of enteric coprecipitates of a poorly soluble drug. J Pharm Sci 83:566-570. http://dx.doi.org/10.1002/jps.2600830425.
44. Miller DA, DiNunzio JC, Yang W, McGinity JW, Williams RO, III. 2008. Targeted intestinal delivery of supersaturated itraconazole for improved oral absorption. Pharm Res 25:1450-1459. http://dx.doi.org/10 .1007/s11095-008-9543-1.
45. Lentz KA. 2008. Current methods for predicting human food effect. AAPS J 10:282-288. http://dx.doi.org/10.1208/s12248-008-9025-8.
46. Psachoulias D, Vertzoni M, Goumas K, Kalioras V, Beato S, Butler J, Reppas C. 2011. Precipitation in and supersaturation of contents of the upper small intestine after administration of two weak bases to fasted adults. Pharm Res 28:3145-3158. http://dx.doi.org/10.1007/s11095-011 -0506-6.
47. Carver PL, Fleisher D, Zhou SY, Kaul D, Kazanjian P, Li C. 1999. Meal composition effects on the oral bioavailability of indinavir in HIVinfected patients. Pharm Res 16:718-724. http://dx.doi.org/10.1023 /A:1018880726035.
48. Purkins L, Wood N, Kleinermans D, Greenhalgh K, Nichols D. 2003. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br J Clin Pharmacol 56:17-23. http://dx.doi.org/10.1046/j.1365 -2125.2003.01994.x.
49. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. 2004. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 57:218-222.
50. Krishna G, Moton A, Ma L, Medlock MM, McLeod J. 2009. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 53:958-966. http://dx.doi.org/10.1128/AAC.01034-08.
51. Singh BN. 1999. Effects of food on clinical pharmacokinetics. Clin Pharmacokinet 37:213-255. http://dx.doi.org/10.2165/00003088-199937030 -00003.
52. Fotaki N, Klein S. 2013. Mechanistic understanding of the effect of PPIs and acidic carbonated beverages on the oral absorption of itraconazole based on absorption modeling with appropriate in vitro data. Mol Pharm 10:4016-4023. http://dx.doi.org/10.1021/mp4003249.
53. Lindahl A, Ungell A-L, Knutson L, Lennern?s H. 1997. Characterization of fluids from the stomach and proximal jejunum in men and women. Pharm Res 14:497-502. http://dx.doi.org/10.1023/A:1012107 801889.
54. Hopkins AM, Wiese MD, Proudman SM, O'Doherty CE, Foster DJR, Upton RN. 2015. Semiphysiologically based pharmacokinetic model of leflunomide disposition in rheumatoid arthritis patients. CPT Pharmacometrics Syst Pharmacol 4:362-371.
55. Bergstrand M, S?derlind E, Eriksson UG, Weitschies W, Karlsson MO. 2012. A semi-mechanistic modeling strategy to link in vitro and in vivo drug release for modified release formulations. Pharm Res 29:695-706. http://dx.doi.org/10.1007/s11095-011-0594-3.
56. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. 2005. Quantification of lean bodyweight. Clin Pharmacokinet 44:1051-1065. http://dx.doi.org/10.2165/00003088-200544100-00004.